Barriers in Concurrent Testing for mNSCLC: Real-world Challe

Experts reflect on the mixed enthusiasm for concurrent liquid and tissue testing, addressing insurance coverage concerns and the importance of shortening turnaround time, while highlighting efforts to make comprehensive testing the default in the community.

Related Keywords

, Precision Oncology , Molecular Genotyping , Optimal Treatment , Metastatic Nonsquamous , Concurrent Testing , Real World Challenges , Nsclc , Non Small Cell Lung Cancer , Liquid And Tissue Testing , Insurance Coverage , Targetable Alterations , Personalized Care , Liquid Biopsy , Tissue Biopsy , Clinical Trials , Comprehensive Testing ,